FIL Study on ABVD DD-DI as Upfront Therapy in HL.

NCT03159897 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Doxorubicin
DRUG: Bleomycin
DRUG: Vinblastine
DRUG: Dacarbazine

Sponsor

Fondazione Italiana Linfomi - ETS